Jordana E Hoppe
Overview
Explore the profile of Jordana E Hoppe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hoppe J, Zemanick E, Martiniano S
Am J Respir Crit Care Med
. 2022 Aug;
206(11):1308-1310.
PMID: 35947636
No abstract available.
12.
Hoppe J, Wagner B, Harris J, Rowe S, Heltshe S, DeBoer E, et al.
J Cyst Fibros
. 2022 Apr;
21(6):950-958.
PMID: 35440409
Background: Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator for people with CF and the G551D mutation. We aimed to investigate the biology of CFTR modulation and systemic...
13.
Hoppe J, Chilvers M, Ratjen F, McNamara J, Owen C, Tian S, et al.
Lancet Respir Med
. 2021 May;
9(9):977-988.
PMID: 33965000
Background: A previous phase 3 study showed that lumacaftor-ivacaftor was generally safe and well tolerated over 24 weeks of treatment in children aged 2-5 years with cystic fibrosis homozygous for...
14.
Lenhart-Pendergrass P, Anthony M, Sariyska S, Andrews A, Scavezze H, Towler E, et al.
Pediatr Pulmonol
. 2021 Apr;
56(7):2043-2047.
PMID: 33847465
Background: Collection of respiratory cultures for airway microbiology surveillance is an essential component of routine clinical care in cystic fibrosis (CF). The COVID-19 global pandemic has necessitated increased use of...
15.
Hoppe J, Hinds D, Colborg A, Wagner B, Morgan W, Rosenfeld M, et al.
Pediatr Pulmonol
. 2020 Sep;
55(12):3400-3406.
PMID: 32970375
Introduction: Oral antibiotics are frequently prescribed for outpatient pulmonary exacerbations (PEx) in children with cystic fibrosis (CF). This study aimed to characterize oral antibiotic use for PEx and treatment outcomes...
16.
Hoppe J, Guimbellot J, Martiniano S, Toprak D, Davis C, Daines C, et al.
Pediatr Pulmonol
. 2020 Jun;
55(9):2225-2232.
PMID: 32573948
This review briefly summarizes presentations in several major topic areas at the conference: pathophysiology and basic science of cystic fibrosis lung disease, clinical trials, clinical quality improvement, microbiology and treatment...
17.
Hoppe J, Sagel S
Am J Respir Crit Care Med
. 2019 Mar;
200(5):528-529.
PMID: 30875233
No abstract available.
18.
Hoppe J, Wagner B, Accurso F, Zemanick E, Sagel S
J Cyst Fibros
. 2018 Jun;
17(6):760-768.
PMID: 29921503
Background: Pulmonary exacerbations (PEx) in children with cystic fibrosis (CF) are frequently treated in the outpatient setting with oral antibiotics. However, little is known about the characteristics of PEx managed...
19.
Hoppe J, Wagner B, Sagel S, Accurso F, Zemanick E
BMC Pulm Med
. 2017 Dec;
17(1):188.
PMID: 29228933
Background: Pulmonary exacerbations (PEx) in school aged children and adults with cystic fibrosis (CF) lead to increased morbidity and lung function decline. However, the effect of exacerbations in young children...
20.